Roman Butler Fullerton & Co. Sells 527 Shares of UnitedHealth Group Incorporated (NYSE:UNH)

Roman Butler Fullerton & Co. cut its stake in shares of UnitedHealth Group Incorporated (NYSE:UNH) by 49.5% in the 4th quarter, Holdings Channel.com reports. The fund owned 537 shares of the healthcare conglomerate’s stock after selling 527 shares during the period. Roman Butler Fullerton & Co.’s holdings in UnitedHealth Group were worth $292,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. International Assets Investment Management LLC boosted its position in shares of UnitedHealth Group by 78,814.4% during the third quarter. International Assets Investment Management LLC now owns 5,296,737 shares of the healthcare conglomerate’s stock valued at $3,096,896,000 after buying an additional 5,290,025 shares during the last quarter. Accredited Investors Inc. boosted its position in shares of UnitedHealth Group by 9,235.4% during the third quarter. Accredited Investors Inc. now owns 784,924 shares of the healthcare conglomerate’s stock valued at $458,929,000 after buying an additional 776,516 shares during the last quarter. Raymond James & Associates boosted its position in shares of UnitedHealth Group by 33.1% during the third quarter. Raymond James & Associates now owns 2,361,396 shares of the healthcare conglomerate’s stock valued at $1,380,661,000 after buying an additional 587,088 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec boosted its position in shares of UnitedHealth Group by 129.7% during the third quarter. Caisse DE Depot ET Placement DU Quebec now owns 1,029,540 shares of the healthcare conglomerate’s stock valued at $601,951,000 after buying an additional 581,324 shares during the last quarter. Finally, State Street Corp boosted its position in UnitedHealth Group by 1.3% in the third quarter. State Street Corp now owns 45,540,102 shares of the healthcare conglomerate’s stock worth $26,626,387,000 after purchasing an additional 563,554 shares during the last quarter. 87.86% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Truist Financial dropped their target price on UnitedHealth Group from $625.00 to $610.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. StockNews.com raised UnitedHealth Group from a “hold” rating to a “buy” rating in a research report on Thursday, January 23rd. Deutsche Bank Aktiengesellschaft lifted their price objective on UnitedHealth Group from $595.00 to $625.00 and gave the company a “buy” rating in a research report on Tuesday, December 3rd. Hsbc Global Res raised UnitedHealth Group from a “hold” rating to a “strong-buy” rating in a research report on Friday, January 10th. Finally, HSBC raised UnitedHealth Group from a “hold” rating to a “buy” rating and set a $595.00 price objective on the stock in a research report on Friday, January 10th. One equities research analyst has rated the stock with a hold rating, twenty have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $629.32.

UnitedHealth Group Price Performance

UNH opened at $523.48 on Friday. The business has a fifty day moving average of $523.11 and a 200 day moving average of $563.18. UnitedHealth Group Incorporated has a 52-week low of $436.38 and a 52-week high of $630.73. The company has a quick ratio of 0.91, a current ratio of 0.83 and a debt-to-equity ratio of 0.74. The stock has a market cap of $481.75 billion, a P/E ratio of 33.77, a PEG ratio of 1.45 and a beta of 0.61.

UnitedHealth Group (NYSE:UNH) last posted its quarterly earnings data on Thursday, January 16th. The healthcare conglomerate reported $6.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.74 by $0.07. UnitedHealth Group had a return on equity of 26.69% and a net margin of 3.60%. The company had revenue of $100.81 billion during the quarter, compared to analysts’ expectations of $101.60 billion. During the same quarter in the previous year, the business earned $5.83 EPS. UnitedHealth Group’s revenue was up 6.8% compared to the same quarter last year. As a group, sell-side analysts anticipate that UnitedHealth Group Incorporated will post 29.54 EPS for the current year.

Insiders Place Their Bets

In related news, Director Timothy Patrick Flynn purchased 1,000 shares of UnitedHealth Group stock in a transaction dated Friday, January 17th. The stock was purchased at an average cost of $511.57 per share, with a total value of $511,570.00. Following the transaction, the director now owns 4,500 shares in the company, valued at approximately $2,302,065. The trade was a 28.57 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.33% of the company’s stock.

UnitedHealth Group Profile

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.